Bruce Stephens
Well-Known Member
- Relationship to Diabetes
- Type 1
Don't be silly! You mention one which was limited in its use (and got very little use in the EU).During the covid vaccine rollout for example, there was no limit (as far as I can see) given on adverse events or deaths e.g the products were never halted,
Medicines are different to (say) teaspoons. There's no major cost in banning some specific kind of teaspoon. But medicines will generally do some good and some harm, so banning one will (while removing its harms) also remove its benefits. The Ox/AZ C19 vaccine continued in use in some countries because its known risks were more than balanced by the benefits it provided. In the UK we stopped use earlier because the mRNA vaccines were readily available, but they're harder to provide in some countries making the Ox/AZ vaccine still a win (while it risked causing deaths in a small proportion of people).
Similarly, there's an argument that OPV is still worth using in much of the world even though it's known to spread, potentially causing paralysis and death, but much less paralysis and death than without vaccination. (I'm not entirely persuaded: I think we should try harder to offer IPV. But I don't think it's a crazy argument to make, though it seems to me to be incompatible with the drive to eliminate the virus.)
Sometimes. Sometimes the evidence takes a while to emerge, sometimes it takes a while before there's a good alternative (and so even with the risks, the benefits make it worthwhile), and I'm sure sometimes regulators incorrectly fail to act.Sometimes it can take 20 years before anyone acts and pulls the product.